Tirzepatide Vs Retatrutide Next Gen Glp1

The GLP-1 space is evolving fast. If you're following the science, you've probably heard the buzz around tirzepatide vs retatrutide (two medications that represent the latest of incretin-based therapy. Tirzepatide is already available and changing the game. Retatrutide is in late-stage clinical trials and generating extraordinary data.

Key Takeaways: - Learn how each medication works - Clinical Trial Results So Far - Side Effects and Safety Comparison - Understand what this means for you today

What makes them different? What do the early results show? And what does it mean for your treatment options? Let's look at the facts.

How Each Medication Works

Feature	Tirzepatide (Zepbound)	Retatrutide
Mechanism	Dual agonist (GLP-1 + GIP)	Triple agonist (GLP-1 + GIP + glucagon)
Weight loss (trials)	~22.5% (SURMOUNT-1 (Jastreboff et al., NEJM, 2022))	~24% (Phase 2)
FDA status	Approved (2023)	Phase 3 trials
Dosing	Weekly injection	Weekly injection
Unique feature	GIP receptor activation	Glucagon-driven fat oxidation
Availability	Prescribed now	Not yet available

"The conversation about obesity needs to shift from willpower to biology. These medications work because obesity is a neuroendocrine disease, not a character flaw.") Dr. Fatima Cody Stanford, MD, MPH, Massachusetts General Hospital

Tirzepatide is a dual GIP/GLP-1 receptor agonist. It activates two incretin hormone receptors simultaneously. GLP-1 reduces appetite, slows gastric emptying, and improves insulin secretion. GIP (glucose-dependent insulinotropic polypeptide) adds another layer (it also stimulates insulin, may affect fat metabolism, and appears to enhance the GLP-1 effects.

This dual mechanism is what separates tirzepatide from earlier GLP-1-only drugs. Two receptors, two pathways, potentially better results.

Retatrutide takes it a step further. It's a triple agonist) targeting GLP-1, GIP, and glucagon receptors simultaneously. That glucagon receptor adds something entirely new to the equation. Glucagon is traditionally known for raising blood sugar (the opposite of insulin), but when activated alongside GLP-1 and GIP, it appears to boost energy expenditure and fat oxidation.

Think of it as a progression: single (GLP-1 only), dual (GLP-1 + GIP), triple (GLP-1 + GIP + glucagon). Each step adds another metabolic lever. More levers doesn't automatically mean better outcomes for every person, but the early data is compelling.

If you're interested in currently available GLP-1 options, to see what's right for you today.

Clinical Trial Results So Far

Tirzepatide has extensive clinical data from the SURPASS (diabetes) and SURMOUNT (weight management) trial programs. In SURMOUNT-1, tirzepatide 15 mg produced average weight loss of 22.5% of body weight over 72 weeks. Roughly 40% of participants lost at least 25% of their body weight. These results were unprecedented for a medication.

---

Free Download: Decision Matrix Current vs next-gen GLP-1 medications (what's available now, what's coming, and how to make decisions today. Get yours free) we'll email it to you instantly. [Download Now]

---

Retatrutide's phase 2 trial data, published in the New England Journal of Medicine in 2023, showed even more dramatic results. At the highest dose tested (12 mg weekly), participants lost an average of 24.2% of body weight over 48 weeks. Some participants lost over 30% of their body weight. At 48 weeks, the weight loss curves had not yet plateaued (suggesting even greater losses with longer treatment.

These numbers are approaching what was previously only achievable with bariatric surgery. For context, gastric bypass typically produces 25-35% body weight loss over 1-2 years.

Important caveats: Retatrutide's data comes from a phase 2 trial with fewer participants. Phase 3 trials are ongoing, and final results will determine whether the medication receives regulatory approval. Phase 2 results don't always hold up in larger phase 3 studies. Tirzepatide's data is more mature and comes from multiple large-scale trials.

For a breakdown into tirzepatide specifically, see our .

Side Effects and Safety Comparison

Both medications share the GLP-1-related side effect profile: nausea, vomiting, diarrhea, constipation, and decreased appetite. These gastrointestinal effects are the most common adverse events and typically improve during dose titration.

Tirzepatide's safety profile is well-characterized from its large trial program. Nausea affected about 25-30% of participants, with most cases being mild to moderate. Discontinuation due to side effects was relatively low. The medication carries the standard GLP-1 class warnings about thyroid tumors (from animal data), pancreatitis, and gallbladder disease.

Retatrutide introduces new considerations because of the glucagon receptor activation. Glucagon raises blood sugar, which seems counterproductive in a metabolic medication. In trials, retatrutide actually improved blood sugar control overall) the GLP-1 and GIP components appear to overpower glucagon's hyperglycemic effect.

However, glucagon receptor activation may affect liver function. Phase 2 trials showed mild elevations in liver enzymes (ALT) in some retatrutide participants. Whether this is clinically significant will be determined in larger, longer trials. Increased heart rate was also observed with retatrutide, which warrants monitoring.

GI side effects in the retatrutide phase 2 trial were frequent (nausea affected about 35-45% of participants at higher doses. Vomiting was more common than with tirzepatide. The triple-agonist mechanism may produce more intense GI effects, though optimized titration schedules could mitigate this.

Learn how to manage GI symptoms in our .

What This Means for You Today

If you need a GLP-1 medication now, tirzepatide is available and produces remarkable results. It's the most effective approved weight loss medication by a significant margin. Compounded tirzepatide may be available through licensed 503A pharmacies with a valid prescription. for current options.

Retatrutide is not yet available outside of clinical trials. If current timelines hold, it may receive FDA approval in the next few years. Until then, it's a promising future option but not a current treatment choice.

Should you wait for retatrutide? In most cases, no. The difference between tirzepatide and retatrutide in trial data (about 2 percentage points of additional weight loss at comparable timepoints) is meaningful but not significant. Meanwhile, starting treatment now means addressing your health goals now rather than waiting years for a marginally better option.

The incretin therapy space is moving quickly. After retatrutide, additional candidates are in the pipeline with even more receptor combinations. The trajectory is clear: treatments are getting more effective over time. But the best medication is the one available to you now that addresses your needs.

Semaglutide remains an excellent option too. Learn more in our .

Frequently Asked Questions

When will retatrutide be available?

Retatrutide is currently in phase 3 clinical trials. If trials succeed and regulatory approval proceeds on schedule, it could potentially reach the market within the next few years. Exact timelines depend on trial completion and FDA review. Tirzepatide and semaglutide are available now.

Is retatrutide significantly better than tirzepatide?

Phase 2 data suggests retatrutide may produce slightly more weight loss than tirzepatide at similar timepoints (24.2% vs 22.5%). However, the retatrutide data is from a smaller, earlier-stage trial. Phase 3 results will provide a clearer comparison. Both medications produce historically impressive weight loss results.

Could retatrutide's glucagon activity cause problems?

The glucagon receptor activation in retatrutide raises theoretical concerns about blood sugar elevation and liver effects. In phase 2 trials, blood sugar control actually improved overall, and liver enzyme elevations were mild. Ongoing phase 3 trials will provide more full safety data. This is one reason why regulatory approval requires extensive testing.

Should I wait for newer medications or start treatment now?

For most people, starting an available treatment now is better than waiting. Excess weight and metabolic conditions carry ongoing health risks. Tirzepatide and semaglutide are highly effective, well-studied medications available today. You can always discuss transitioning to newer options with your provider as they become available.

Let's Make This Happen

The research is clear. The options are available. The only question is whether it's right for you. A FormBlends provider can help you decide (no pressure, no commitment.

---

Sources & References

1. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. Doi:10.1056/NEJMoa2032183
2. Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2 (Davies et al., Lancet, 2021)). Lancet. 2021;397(10278):971-984. Doi:10.1016/S0140-6736(21)00213-0
3. Wadden TA, Bailey TS, Billings LK, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3 (Wadden et al., JAMA, 2021)). JAMA. 2021;325(14):1403-1413. Doi:10.1001/jama.2021.1831
4. Garvey WT, Batterham RL, Bhatt DL, et al. Two-Year Effects of Semaglutide in Adults with Overweight or Obesity (STEP 5 (Garvey et al., Nat Med, 2022)). Nat Med. 2022;28:2083-2091. Doi:10.1038/s41591-022-02026-4
5. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. Doi:10.1056/NEJMoa2307563
6. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. Doi:10.1056/NEJMoa2206038
7. Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2 (Garvey et al., Lancet, 2023)). Lancet. 2023;402(10402):613-626. Doi:10.1016/S0140-6736(23)01200-X
8. Wadden TA, Chao AM, Engel S, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity (SURMOUNT-3 (Wadden et al., Nat Med, 2023)). Nat Med. 2023. Doi:10.1038/s41591-023-02597-w
9. Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity (SURMOUNT-4 (Aronne et al., JAMA, 2024)). JAMA. 2024;331(1):38-48. Doi:10.1001/jama.2023.24945
10. Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med. 2024;391:1193-1205. Doi:10.1056/NEJMoa2404881
11. Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373(1):11-22. Doi:10.1056/NEJMoa1411892
12. Marso SP, Daniels GH, Tanaka K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375(4):311-322. Doi:10.1056/NEJMoa1603827

Nothing in this article should be construed as medical advice. The information provided is educational only. Always consult with your healthcare provider before beginning, modifying, or discontinuing any medication or treatment. FormBlends connects patients with licensed providers for individualized care.

Last updated: 2026-03-24